Document is current
Any future updates will be listed below
-
Authors
Raghavendra, Akshara Singareeka https://orcid.org/0000-0002-6425-4400
Kettner, Nicole M. https://orcid.org/0000-0003-2043-4407
Kwiatkowski, Danielle
Damodaran, Senthil
Wang, Yan https://orcid.org/0000-0001-9566-8975
Ramirez, David
Gombos, Dan S.
Hunt, Kelly K. https://orcid.org/0000-0001-9156-8723
Shen, Yu https://orcid.org/0000-0002-3899-7868
Keyomarsi, Khandan https://orcid.org/0000-0002-5440-0849
Tripathy, Debu https://orcid.org/0000-0002-5711-2404
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP170079, RP180712, RP180712, RP170079, RP180712)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA255960, CA223772)
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 13 January 2025
First Online: 26 January 2025
Competing interests
: D.T.: Quantum Leap Healthcare. K.K.H.: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell. K.K.: Apeiron, BluePrint, REPARE, Schrodinger and Novartis. The authors declare no competing interests.
